Add BrightSurf on Google Email

Science News for August 31, 2008


The TRANSCEND study

The TRANSCEND study found that telmisartan modestly reduced the outcome of cardiovascular death, heart attack, stroke, and hospitalization for heart failure. Additionally, fewer patients receiving telmisartan were hospitalized for any cardiovascular reason compared to placebo.

Who needs surgery?

Recent guidelines reject CABG as initial treatment strategy for most patients with multi-vessel disease, despite evidence suggesting otherwise. A multidisciplinary approach involving a surgeon is recommended to ensure patients receive balanced advice.

The BEAUTIFUL study

The BEAUTIFUL study shows ivabradine significantly reduces hospitalization for fatal and non-fatal myocardial infarction by 36% and coronary revascularisation by 30% in high-heart-rate patients. Ivabradine is safe and well-tolerated, even when used with other cardiovascular drugs.

Genetic testing?

Genetic testing has significantly improved the detection of individuals at risk for sudden cardiac death in athletes. This technology enables informed decision-making regarding care and training continuation among athletes. However, its use in asymptomatic genetic carriers with normal phenotypes is a topic of controversy.

Cardiac imaging in 2020

Recent advancements in cardiac imaging have led to the detection of impairments in cellular processes that precede changes in morphology and function. These early stages can be identified through various imaging techniques such as PET, nuclear imaging, MRI, ultrasound, and optical imaging.

Sex hormones link to heart risk

A new study led by the University of Leicester found that men's sex hormones, particularly estradiol and estrone, are associated with increased cardiovascular risk factors such as high total cholesterol and LDL-cholesterol. This suggests that natural endogenous estrogens may play a role in increasing heart disease risk in men.

SourceUniversity of Leicester·JournalAtherosclerosis·DateAug 31, 2008